MSD’s Ontruzant Gets Australian Reimbursement
Follows PBS listings for Ogivri, Herzuma and Kanjinti
Merck Sharp & Dohme’s Ontruzant has become the fourth trastuzumab biosimilar to be reimbursed in Australia, while Pfizer’s Trazimera is in line to be the fifth.
You may also be interested in...
Samsung Bioepis’ Ontruzant trastuzumab biosimilar has become the first biosimilar to be prequalified by the World Health Organization.
Lamivudine combinations with zidovudine, as well as ezetimibe, bosentan and infliximab were among the drugs in the crosshairs for Australian reimbursement price cuts from 1 October.
A body that advises Australia’s Department of Health on reimbursement will in November consider listing applications for Sandoz’ Ziextenzo pegfilgrastim candidate and well as for Pfizer’s recently authorized Trazimera trastuzumab brand.